Table 3

Studies included in the replication meta-analyses

Cohort by ancestryEthnicity/nationalityDM typeAny DR analysisPDR analysisNPDR analysisExtremes of DR analysis
Case subjectsControl subjectsCase subjectsControl subjectsCase subjectsControl subjectsCase subjectsControl subjects
 SCES IChinese275228
 SCES IIChinese22778
 DCCT/EDIC primary cohortNorth American153598
 DCCT/EDIC secondary cohort, conventional treatmentNorth American1114209
 DCCT/EDIC secondary cohort, intensive treatmentNorth American142288
 GoKinDNorth American1138581
 SUMMITEuropean1 and 25,4224,302
 WESDRNorth American1309294
 SCHSMexican American2528247103672406247103247
  • The SUMMIT (SUrrogate markers for Micro- and Macrovascular hard endpoints for Innovative diabetes Tools) cohort is a meta-analysis of three European studies: the Finnish Diabetic Nephropathy (FinnDiane) Study, Scania Diabetes Registry, and the EURODIAB study. DCCT/EDIC, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications; DM, diabetes mellitus; GENESIS/GENEDIAB, Genetics Nephropathy and Sib Pair Study/Génétique de la Nephropathie Diabétique; GoDARTS, Genetics of Diabetes and Audit Research Tayside Study; GoKinD, Genetics of Kidneys in Diabetes; GOLDR, Genetics of Latino Diabetic Retinopathy; KSDR, Korean Study of Diabetic Retinopathy; LALES, Los Angeles Latino Eye Study; MESA, Multiethnic Study of Atherosclerosis; RIKEN, Rikagaku Kenkyusho - Institute of Physical and Chemical Research; SCES, Singapore Chinese Eye Study; SCHS, Starr County Health Studies; SiMES, Singapore Malay Eye Study; SINDI, Singapore Indian Eye Study; TUDR, Taiwan–US Diabetic Retinopathy Study; WESDR, Wisconsin Epidemiologic Study of Diabetic Retinopathy.